This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Trastuzumab

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 10: Line 10:
===Mechanism of Action===
===Mechanism of Action===
-
Human [[Epidermal Growth Factor Receptor]] 2 (HER2)
+
Human [[Epidermal Growth Factor Receptor|Epidermal Growth Factor Receptor 2] (HER2)
===Pharmacokinetics===
===Pharmacokinetics===

Revision as of 14:00, 8 December 2010

Tastuzumab, better known as Herceptin, (3bdy)

Drag the structure with the mouse to rotate

Better Known as: Herceptin

  • Marketed By: Genentech
  • Major Indication: Breast Cancer
  • Drug Class: Human Epidermal Growth Factor Receptor 2 (HER2) Inhibitor
  • Date of FDA Approval (Discontinued): 1998 (2015)
  • 2008 Sales: $4.75 Billion
  • Importance: It is a very effective treatment against HER2-positive metastatic breast cancer compared to other cancer therapies. Controversial due to its cost of nearly $100,000 per year. Is often pointed to as an example of the benefits of personalized medicine in which a patent's genetic profile is used to optimize their medication regimen.
  • The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information

Mechanism of Action

Human [[Epidermal Growth Factor Receptor|Epidermal Growth Factor Receptor 2] (HER2)

Pharmacokinetics

EGFR Inhibitor Pharmacokinetics[1][2]
Parameter Trastuzumab
Tmax (hr) 1.7
Cmax (ng/ml) 203000
Bioavailability (%) 54
T1/2 (days) 27
AUC (ug/ml/hr) 45036
Clearance (L/h) .009
Dosage (mg) 250
Metabolism Unknown

References

  1. ↑ Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 2003 Nov 1;21(21):3965-71. Epub 2003 Sep 24. PMID:14507946 doi:10.1200/JCO.2003.12.109
  2. ↑ B. Leyland-Jones, et al. Pharmacologic insights into the future of trastuzumab. Annals of Oncology 12 (Suppl. I): S43-S47, 2001.


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky, Joel L. Sussman

Retrieved from "http://52.214.119.220/wiki/index.php/Trastuzumab"
Personal tools